

# **DEVELOPMENT OF THE COMBINED MEDICATION COMPOSITION FOR SYMPTOMATIC PSEUDORHEUMATISM TREATMENT**

Serdyuk I.S.

Scientific supervisor : PhD Chushenko V.M.

National Pharmaceutical University , Kharkiv, Ukraine

chushenkov@rambler.ru

A pseudorheumatism (RA) is a chronic disease which has an immune inflammatory nature that leads to profound deformations of the staggered joints and their functional ability violation . Treatment of RA consists in application of two types of preparations: anti-inflammatory and basic.

Due to the information of State form of Ukraine seventh edition by medicinal preparations (LP) which influence the locomotory are anti inflammatory : non-steroid locomotorium preparations: (selective and unselective inhibitors of COG–1 and COG–2) but corticosteroids : betametazon, methylprednisolonum, prednizolon.

To base LP belong: cytostatics; biological preparations which influence on a specific albumen; antimalarial preparations; sulfanilamidums and penicilamin.

The purpose of our research is an analysis of assortment of LP and choice of active pharmaceutical ingredients (AFI) for development of complex composition of soft medical form for symptomatic treatment of RA.

A pharmaceutical market of Ukraine industrial production analysis rotined on 1.03.2017, has shown that an assortment for RA treatment is enough various . For RA treatment uses monocomponent (45) and combined (5) medications which have a different medical form: ointments and gels are 45 % from the general amount of preparations, pill, 32 %, solutions for injections – 12 %, supositorio and capsules – 5 %.

Non-steroid anti inflammatory medications which have an anti inflammatory, analgetic and antipyrogenic action enter in the complement of these preparations. Traditional basis of medical therapy is made by Non-steroid anti-inflammatory medications.

Among medical forms which are used for treatment of RA soft LZ are let in on the ground: possibility of achievement of high therapeutic action of ointments and geley due to combined AFI and them rapid freeing; relative simplicity and unconcern in application by comparison to other by medical forms; economy and technologicalness; comfort and local use.

Thus, the conducted researches allowed to choose active pharmaceutical ingredients for development of the combined gel of extemporal production for symptomatic treatment of pseudorheumatism.